Adamis Pharmaceuticals (NASDAQ:ADMP) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) in a research report issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Stock Performance

Shares of ADMP opened at $0.25 on Friday. The company’s fifty day moving average is $0.36 and its 200 day moving average is $0.44. Adamis Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $1.48.

Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $1.02 million. As a group, sell-side analysts anticipate that Adamis Pharmaceuticals will post -0.18 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Adamis Pharmaceuticals stock. Capital CS Group LLC purchased a new position in Adamis Pharmaceuticals Co. (NASDAQ:ADMPGet Rating) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 70,513 shares of the specialty pharmaceutical company’s stock, valued at approximately $40,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Adamis Pharmaceuticals Company Profile

(Get Rating)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.

Featured Articles

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.